China Medical City To Acquire Korean Biotechnology
This article was originally published in PharmAsia News
Six Korean R&D institutions and eight companies in biopharmaceuticals recently signed MOUs for 16 programs with China Medical City in Jiangsu province. The Daejeon City representatives from Korea will be introducing world-class new drug R&D technologies into China, as well as the industrialization and production of health care and pharmaceutical products. Since its establishment, China Medical City has been targeting Korean investors. Last year, it signed an agreement with its counterpart to set up a center that offers collaborative biopharmaceutical services to Korean enterprises operating in the medical city. (Click here for more - Chinese Language)
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.